论文部分内容阅读
目的评价替莫唑胺治疗复发性脑恶性胶质瘤的疗效及安全性。方法 38例复发的恶性胶质瘤患者给予单药替莫唑胺100-200mg/m2,连续口服5d,28d为一周期。所有患者至少接受两个疗程治疗。替莫唑胺化疗后以头颅MRI判断疗效,并记录相关治疗反应。结果中位随访时间8.5个月。8例患者的肿瘤明显缩小,PR率为21.05%;13例患者肿瘤稳定,SD率为34.24%。中位无进展生存期为5.4个月;17例(44.74%)患者无进展生存期超过6个月;1年生存率23.68%(9/38)。替莫唑胺主要不良反应为恶心、呕吐、乏力和骨髓抑制等。结论口服替莫唑胺对恶性复发性胶质瘤患者安全有效。
Objective To evaluate the efficacy and safety of temozolomide in the treatment of recurrent brain malignant glioma. Methods 38 cases of recurrent malignant glioma patients given single temozolomide 100-200mg / m2, continuous oral 5d, 28d for a cycle. All patients received at least two courses of treatment. Temozolomide to determine the efficacy of cranial MRI, and record the relevant treatment response. Results The median follow-up time was 8.5 months. The tumors of 8 patients were significantly reduced, the PR rate was 21.05%. The tumors of 13 patients were stable and the SD rate was 34.24%. The median progression-free survival was 5.4 months. The progression-free survival of 17 patients (44.74%) was longer than 6 months. The 1-year survival rate was 23.68% (9/38). The main side effects of temozolomide were nausea, vomiting, fatigue and bone marrow suppression. Conclusion Oral temozolomide is safe and effective for patients with malignant recurrent glioma.